Loading...
XTAI
6541
Market cap231mUSD
Oct 30, Last price  
28.50TWD
1D
-4.68%
1Q
-23.59%
Jan 2017
-81.40%
IPO
-72.98%
Name

Tanvex BioPharma Inc

Chart & performance

D1W1MN
XTAI:6541 chart
P/E
—
P/S
18.84
EPS
—
Vol. 1Y
41.61%
Shs. 5Y
21.34%
Rev. 5Y
321.89%
Div Yld LY
—
Div Yld TTM
—
Revenues
401m
+1,056.27%
0000000300,0005,406,00022,404,00061,411,00034,678,000400,971,000
Net income
-1.50b
L+8.59%
-299,032,000-472,485,000-835,255,000-1,244,446,000-1,409,800,000-1,893,862,000-2,274,226,000-2,104,236,000-1,543,211,000-1,641,130,000-2,137,101,000-1,381,550,000-1,500,157,000
CFO
-1.01b
L-12.62%
-239,857,000-434,173,000-684,195,000-833,426,000-1,212,016,000-1,605,885,000-1,898,660,000-1,787,625,000-1,387,021,000-1,333,847,000-1,433,809,000-1,150,599,000-1,005,441,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Tanvex BioPharma, Inc., originally known as Ruenvex Biotech, Inc., is a biopharmaceutical company founded in 2013 and based in George Town, Cayman Islands. The firm specializes in the investigation, creation, production, and sale of biosimilar medicines, with its operations spanning Taiwan and the United States. Its core mission involves developing biosimilars aimed at treating severe conditions like neutropenia, breast cancer, metastatic colorectal cancer, and psoriasis. The company's robust product portfolio includes TX01 and TX-05, both of which have successfully completed Phase III clinical trials. Additionally, TX-04 and TX-16 are currently undergoing Phase I clinical trials, while TX-52 and other potential therapies are in the pre-clinical development stage.

Key people

Junyi Luan
Chief Financial Officer, Corporate Governance Officer · since 2024
Jennifer Kuan
Deputy General Manager-Operations · since 2025
Helena Makagiansar
Deputy General Manager-LJB Production Development · since 2014
Mike Parker
Senior Deputy General Manager-Technology · since 2018
Yongjian Wu
Deputy General Manager-LJB Research & Development · since 2011
Kaiwen Yang
Deputy General Manager-LJB Production · since 2015
Marc Goemans
Chief Commercial Officer · since 2025
James Williamson
Head of Accounting · since 2024
Allen Chao
Director · since 2021
Lin Cheng Chen
Director · since 2025
Chi-Chuan Chen
Director · since 2020
Stephen Lam
Chief Executive Officer, Director · since 2025
Pao-Shi Sheng
Chairman of the Board · since 2025
Yen-Shu Chang
Independent Director · since 2025
Chi-feng Chang
Independent Director · since 2024
Shang-Hsien Hsieh
Independent Director
Tay-Chang Wang
Independent Director · since 2021
URL
https://www.tanvex.com/
IPO date
Aug 13, 2015
Employees
Domiciled in
KY
Incorporated in
KY

Valuation

Title
TWD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT